VANCOUVER, British Columbia — November 19, 2025 — Leads & Copy — NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) is undertaking a non-brokered private placement to raise up to US$10,050,000. The financing will involve participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation.
The clinical-stage biopharmaceutical company, which focuses on developing neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, plans to issue up to 4,785,715 units at US$2.10 per unit, according to a press release.
Each unit will comprise one common share of NervGen and one-half of one common share purchase warrant. The warrants will be valid for 36 months after the offering’s closing, with each warrant exercisable for one common share at US$2.65.
NervGen intends to use the proceeds to advance its NVG-291 clinical development program and for general corporate purposes.
SCI Ventures, described as the world’s first specialist venture fund focused on paralysis, is supported by organizations such as the Christopher & Dana Reeve Foundation and Wings for Life. Adrien Cohen, Founding Managing Director of SCI Ventures, stated that his organization is proud to support NervGen.
SCI Ventures brings a global network of clinicians, researchers, regulators, and community leaders dedicated to advancing meaningful innovation in SCI.
Officers and board members of NervGen are also expected to participate in the offering, which is considered a “related party transaction” under Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9.
The company is relying on exemptions from formal valuation and minority shareholder approval requirements, as the value of securities issued to related parties is not expected to exceed 25% of NervGen’s market capitalization.
The Non-Brokered Unit Offering is subject to the approval of the TSX Venture Exchange and is expected to close around November 19, 2025. Securities issued will be subject to a four-month hold period as per Canadian securities laws.
NVG-291, NervGen’s lead candidate, is a therapeutic peptide targeting nervous system repair, licensed from Case Western Reserve University.
The company has received Fast Track designation from the FDA and Orphan Designation from the EMA for NVG-291 in individuals with spinal cord injury.
Adam Rogers, MD, Interim Chief Executive Officer of NervGen, said that the expected financing reflects growing conviction in the company’s clinical progress and long-term strategic direction.
NervGen is currently evaluating NVG-291 in a Phase 1b/2a clinical trial (CONNECT SCI Study) for spinal cord injury, with enrollment ongoing for the subacute cohort.
NervGen’s website provides more details on participating in the study.
Huitt Tracey, Investors: htracey@nervgen.com, 604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media, Russo Partners: David.Schull@russopartnersllc.com, Ignacio.Guerrero-Ros@russopartnersllc.com, 858.717.2310
Source: NervGen Pharma Corp.
